文献速递免疫规划传染病防控与疫情报告

1990-2018年VAERS疫苗后心肌心包炎报告分析

Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
PubMed 文献 · Vaccine · 2021-01-06

该研究对1990-2018年VAERS收到的美国疫苗后心肌心包炎报告进行描述性分析,共708份报告符合病例定义或由医生诊断。报告以男性为主(79%),69%为严重报告,72%在接种后2周内出现症状;天花疫苗(59%)和炭疽疫苗(23%)报告最多,数据挖掘仅显示天花疫苗存在不成比例报告。

要点

  • 疫苗后心肌心包炎在VAERS中仍属罕见报告,总体占0.1%。
  • 报告最常见于天花疫苗,其次为炭疽疫苗;不同年龄组常见疫苗不同。
  • 72%的报告在接种后2周内出现症状,69%为严重报告。

核心结论

  • 尽管多年来引入新疫苗,美国许可疫苗后心肌心包炎在VAERS中仍罕见报告。
  • 本分析中心肌心包炎最常在天花疫苗后报告,其他疫苗后较少见。

研究设计与样本

  • 对1990-2018年VAERS收到的美国报告进行描述性分析,纳入符合已发表心肌心包炎病例定义或由医生诊断的报告。
  • 按年龄组(<19、19-49、≥50岁)分层,描述严重/非严重状态、性别、症状出现时间、接种疫苗及暴露于其他已知原因。
  • 使用经验贝叶斯数据挖掘检测疫苗接种后心肌心包炎的不成比例报告。

主要发现

  • VAERS在1990-2018年共收到620,195份报告,其中708份(0.1%)符合病例定义或由医生诊断为心肌心包炎。
  • 79%的心肌心包炎报告描述男性,69%为严重报告,72%在接种后≤2周出现症状。
  • 总体报告最多的疫苗为天花疫苗(59%)和炭疽疫苗(23%)。
  • 按年龄组:<19岁中b型流感嗜血杆菌疫苗(22,22%)和乙肝疫苗(18,18%)最多;19-49岁中天花疫苗(387,79%)最多;≥50岁中灭活流感疫苗(31,36%)和减毒活带状疱疹疫苗(19,22%)最多。
  • 排除138份描述其他已知原因的报告后,最常报告的疫苗保持不变;数据挖掘仅显示天花疫苗后心肌心包炎存在不成比例报告。

临床怎么用

  • 在接种天花疫苗后需关注心肌心包炎的罕见报告,尤其男性及接种后2周内。
  • 其他美国许可疫苗后心肌心包炎报告较少,但临床仍需保持监测意识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myopericarditis after vaccination has been sporadically reported in the medical literature. Here, we present a thorough descriptive analysis of reports to a national passive vaccine safety surveillance system (VAERS) of myopericarditis after vaccines licensed for use in the United States. METHODS: We identified U.S. reports of myopericarditis received by VAERS during 1990-2018 that met a published case definition for myopericarditis or were physician-diagnosed. We stratified analysis by age group (<19, 19-49, ≥50 years), describing reports by serious/non-serious status, sex, time to symptom onset after vaccination, vaccine(s) administered, and exposure to other known causes of myopericarditis. We used Empirical Bayesian data mining to detect disproportionate reporting of myopericarditis after vaccination. RESULTS: VAERS received 620,195 reports during 1990-2018: 708 (0.1%) met the case definition or were physician-diagnosed as myopericarditis. Most (79%) myopericarditis reports described males; 69% were serious; 72% had symptom onset ≤ 2 weeks postvaccination. Overall, smallpox (59%) and anthrax (23%) vaccines were most commonly reported. By age, among persons aged < 19 years, Haemophilus influenzae type b (22, 22%) and hepatitis B (18, 18%); among persons aged 19-49 years smallpox (387, 79%); among persons aged ≥ 50 years inactivated influenza (31, 36%) and live attenuated zoster (19, 22%) vaccines were most commonly reported. The vaccines most commonly reported remained unchanged when excluding 138 reports describing other known causes of myopericarditis. Data mining revealed disproportionate reporting of myopericarditis only after smallpox vaccine. CONCLUSIONS: Despite the introduction of new vaccines over the years, myopericarditis remains rarely reported after vaccines licensed for use in the United States. In this analysis, myopericarditis was most commonly reported after smallpox vaccine, and less commonly after other vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Su JR, McNeil MM, Welsh KJ, et al. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. Vaccine. 2021. PMID: 33422381. doi:10.1016/j.vaccine.2020.12.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。